Understanding Step Edit Requirements in Oncology Care
Login to Watch this Webinar
To watch the live webinar, login to your account or register to gain access to our exclusive content.
Step edit requirements are unfortunately becoming more common in oncology, creating harmful burdens for treatment access and care delivery. Join NCODA’s Step Edits in Oncology Webinar Series to learn about the latest in how this is impacting practices and patients.
This first session in the series will break down what step edits are, how they differ from prior authorizations and other utilization management strategies, and why payers use them. Attendees will gain insight into how Medicare Part D and commercial payers structure step-therapy requirements for treatments, along with the clinical and non-clinical factors that influence payer-mandated sequencing decisions.
Featuring: Melissa Shimanek, PharmD, BCACP (Rocky Mountain Cancer Centers)
Learning Objectives
- Differentiate step edits from prior authorizations and other utilization management strategies.
- Define step edit requirements as they apply to Bruton’s tyrosine kinase inhibitor (BTKi) therapy in oncology.
- Describe how Medicare Part D and commercial payer policies structure step edit therapy for new patient starts.
- Identify clinical and non-clinical factors that influence payer-mandated sequencing of BTKis.
For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.
